Form 4: AYTU CBO Jarrett Disbrow Receives Equity Compensation

AYTU BioPharma's Chief Business Officer, Jarrett Disbrow, was granted 32,106 shares of common stock as part of his compensation, including an annual bonus and restricted stock with a vesting schedule.

Summary

• Jarrett Disbrow, Chief Business Officer of AYTU BioPharma, Inc., acquired a total of 32,106 shares of common stock on October 3, 2025.
• This acquisition included 19,606 shares of fully vested restricted stock granted in lieu of a cash annual bonus.
• An additional 12,500 shares of restricted stock were granted, with 1/3 vesting on October 3, 2026, and the remainder vesting in 8 equal quarterly installments beginning January 3, 2027.
• Following these transactions, Jarrett Disbrow beneficially owns 61,568 shares of AYTU common stock.
• The grants were reported with a transaction price of $0 per share, typical for equity compensation grants.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates continued alignment of management interests with shareholders through equity compensation, which is a routine and generally accepted practice.

Positives

• The grant of restricted stock aligns the Chief Business Officer's interests with those of shareholders, as his compensation is tied to the company's future stock performance.
• Increased insider ownership demonstrates management's continued commitment to the company.

Negatives

• The annual bonus was paid in fully vested restricted stock instead of cash, which could indicate a desire to conserve cash or a strategic decision to further align executive compensation with equity performance.

Risks

• The reporting person faces potential liabilities for non-compliance with Section 13 or Section 16 of the Exchange Act or Rule 144, including disgorgement of profits under Section 16(b) of the Exchange Act, as outlined in the Power of Attorney.
• The value of the restricted stock is subject to market fluctuations, posing a risk to the ultimate value of the compensation received by the reporting person.

Future Outlook

The future outlook for Jarrett Disbrow's equity holdings includes the vesting of 12,500 restricted stock shares, with the first tranche vesting on October 3, 2026, and subsequent quarterly vesting through 2027 and beyond, contingent on continued employment and company performance.

Industry Context

Equity compensation, particularly through restricted stock grants, is a common practice in the biotechnology and pharmaceutical industries. It serves to attract and retain key talent, align executive incentives with long-term shareholder value creation, and manage cash flow by deferring cash compensation.

Comparison to Industry Standards

• Executive equity compensation, including restricted stock grants and performance-based awards, is a standard practice across the biopharmaceutical industry, similar to companies like Pfizer, Moderna, or Johnson & Johnson, though specific grant sizes and vesting schedules vary based on company size, executive role, and performance metrics.
• The use of restricted stock in lieu of a cash bonus is also a recognized method for companies to conserve cash while still rewarding executives and strengthening their alignment with shareholder interests, a strategy observed in various growth-oriented or cash-conscious firms.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment of the Chief Business Officer's financial interests with shareholder value through equity compensation.
• Employees: The compensation structure for a key executive may set a precedent or reflect broader compensation philosophies within the company.

Next Steps

• The vesting of 1/3 of the 12,500 restricted stock grant on October 3, 2026.
• The commencement of quarterly vesting installments for the remaining restricted stock beginning January 3, 2027.

Key Dates

Recommendation

This Form 4 filing reports routine equity compensation for a company officer and does not contain new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It primarily confirms an expected aspect of executive compensation.

Keywords

AYTU, BioPharma, Form 4, Insider Transaction, Equity Compensation, Restricted Stock, Jarrett Disbrow, Chief Business Officer